COGENT BIOSC.INC.DL-,001 Logo
US19240Q2012
A2QJAY
COGT

COGENT BIOSC.INC.DL-,001

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 46,10 (+82,00%). A mediana é € 47,31 (+86,77%).

Comprar
  10
Manter
  2
Vender
  0

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Cogent Bioscience files FDA application for bezuclastinib to treat advanced systemic mastocytosis

    Cogent Bioscience filed a New Drug Application with the U.S. FDA for bezuclastinib on June 30, supported by encouraging results from the APEX pivotal trial. CEO Andrew Robbins said the company is engaging closely with the FDA on three submissions and expects initial approvals by the end of 2026. The company is also advancing a JAK2 V617F mutation‑specific inhibitor with plans to file an IND in 2026. Bezuclastinib is a selective tyrosine kinase inhibitor targeting KIT mutations and is approaching Phase 3 development. » Mais em finance.yahoo.com


  • Cogent Biosciences presents preclinical data showing mutant‑selective JAK2 inhibitor CGT1145 with >100‑fold selectivity

    Cogent Biosciences reported early preclinical results for CGT1145 showing more than 100‑fold selectivity for JAK2 V617F over wild‑type JAK2 and JAK1/3, suggesting reduced off‑target effects that can cause low blood counts. The compound demonstrated strong oral bioavailability, consistent pharmacology across models, and potential to eradicate disease‑driving cells and support molecular remission in JAK2 V617F‑driven blood cancers. Cogent said it remains on track to file an Investigational New Drug application with the FDA later this year. » Mais em finance.yahoo.com


  • Cogent Biosciences projects >$3bn peak sales for bezuclastinib amid near-term regulatory catalysts

    Cogent Biosciences is advancing bezuclastinib, a selective KIT D816V inhibitor, with NDAs accepted for indolent systemic mastocytosis (PDUFA Dec 2026) and imminent submission for advanced disease, and an RTOR NDA for second-line GIST where trials showed improved PFS versus standard care. The company also develops additional oncology assets (pan-KRAS, JAK2, FGFR2/3) that broaden its commercial optionality. Analysts and investors view Cogent as an attractive M&A target given de-risked data, multiple near-term catalysts and projected multibillion-dollar sales, though safety and competition remain risks. » Mais em finance.yahoo.com


  • Kynam Capital trims $48M position in Cogent Biosciences but leaves it as top holding

    Kynam Capital Management sold 1,720,949 shares of Cogent Biosciences in Q4, an estimated $48.38 million reduction based on quarterly average pricing, while the position still represents about 14% of reported AUM and remains the fund's largest holding. Cogent shares have surged roughly 360% over the past year and trade at $33.38 as of Friday. Recent catalysts include FDA acceptance of bezuclastinib’s filing with a December 30 target action date and year-end cash of $900.8 million, supporting operations into 2028. The sale appears to be a risk-management trim rather than a shift in conviction according to the filing and portfolio context. » Mais em finance.yahoo.com


  • Cogent Biosciences advances bezuclastinib NDAs after positive pivotal trials and secures strong cash runway

    Cogent Biosciences reported 2025 regulatory momentum for lead candidate bezuclastinib following three positive pivotal trials and submitted an NDA for Non-Advanced Systemic Mastocytosis in December 2025, with an Advanced Systemic Mastocytosis NDA expected in H1 2026. The company is also completing a rolling NDA for second-line GIST under the FDA Real-Time Oncology Review, supported by PEAK trial data showing median progression-free survival of 16.5 months. Cogent maintains a robust pipeline including CGT1145 and CGT1815 and ended 2025 with $900.8 million in cash and marketable securities, funded partly by a $546.8 million offering and projected to finance operations into 2028. » Mais em finance.yahoo.com

Dados financeiros da empresa

No último trimestre, COGENT BIOSC.INC.DL-,001 registou receitas de € 0 e um ganho líquido de -€ 98,37 mi
(EUR) setembro de 2026
YoY
Receitas 0 -
Ganho bruto 0 -
Ganho líquido -98,37 mi 42,65%
EBITDA -96,77 mi 44,99%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 4,52 bi
Número de ações
173,99 mi
Máximo/mínimo de 52 semanas
€ 39,79 - € 25,23
Dividendos Não
Beta
0,34
PER (PE Ratio)
-12,31
PEG (PEG Ratio)
-2,02
P/VC (PB Ratio)
9,58
P/V (PS Ratio)
0,00

Perfil da empresa

A Cogent Biosciences, Inc., uma empresa de biotecnologia, dedica-se ao desenvolvimento de terapias de precisão para doenças geneticamente definidas. O seu principal candidato a produto inclui o CGT9486, um inibidor seletivo da tirosina quinase concebido para inibir a mutação KIT D816V, que impulsiona a mastocitose sistémica, bem como outras mutações no exão 17 do KIT, encontradas em doentes com tumores do estroma gastrointestinal avançados. A empresa tem um acordo de licenciamento com a Plexxikon Inc. para a investigação, desenvolvimento e comercialização do bezuclastinib. A empresa era anteriormente conhecida como Unum Therapeutics Inc. e mudou o seu nome para Cogent Biosciences, Inc. em outubro de 2020. A Cogent Biosciences, Inc. foi constituída em 2014 e tem sede em Cambridge, Massachusetts.

Nome
COGENT BIOSC.INC.DL-,001
CEO
Andrew R. Robbins
Sede Waltham, ma
EUA
Site
Setor
Materiais básicos
Indústria
Produtos químicos
Entrada em bolsa
29/03/2018
Colaboradores 258

Símbolos de ticker

Bolsa Símbolo
NASDAQ
COGT
🍪

Parqet  utiliza cookies. Saber mais